What Are Research Peptides?

Peptides are short chains of amino acids (typically 2–50) that serve as signaling molecules in biological systems. Research peptides are synthetic versions of naturally occurring peptides, manufactured to pharmaceutical-grade purity for use in laboratory and in-vitro research settings. They are not drugs, supplements, or approved therapeutics.

Semaglutide

GLP-1 RECEPTOR AGONIST · METABOLIC

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes. It mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion and suppressing glucagon release. Clinical trials have demonstrated significant effects on body weight reduction, appetite regulation, and cardiovascular risk markers.

Key references: Wilding et al., 2021 (PMID 33567185) · Marso et al., 2016 (PMID 27295427)

Tirzepatide

DUAL GIP/GLP-1 RECEPTOR AGONIST · METABOLIC

Tirzepatide is the first dual-action incretin compound, activating both GIP and GLP-1 receptors simultaneously. This dual mechanism produces enhanced metabolic effects compared to single GLP-1 agonists. Phase 3 clinical data shows superior weight reduction and glycemic control outcomes versus semaglutide in head-to-head trials.

Key references: Jastreboff et al., 2022 (PMID 35658024) · Frías et al., 2021 (PMID 34170647)

Retatrutide

TRIPLE AGONIST (GIP/GLP-1/GLUCAGON) · METABOLIC

Retatrutide is a next-generation triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. The glucagon component adds thermogenic activity not seen in dual agonists. Phase 2 clinical trials demonstrated it to be among the most effective metabolic compounds ever studied, with unprecedented weight reduction outcomes.

Key references: Jastreboff et al., 2023 (PMID 37366315) · Coskun et al., 2022 (PMID 35953067)

BPC-157

BODY PROTECTION COMPOUND · RECOVERY

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. It is the most extensively studied repair peptide in preclinical research. Animal studies have demonstrated effects on tendon and ligament healing, gut mucosal protection, angiogenesis, and modulation of nitric oxide and growth factor pathways.

Key references: Sikiric et al., 2018 (PMID 30030979) · Gwyer et al., 2019 (PMID 30939294)

CJC-1295 + Ipamorelin

GH SECRETAGOGUE BLEND · GROWTH HORMONE

This pre-mixed blend combines two growth hormone secretagogues with complementary mechanisms. CJC-1295 is a GHRH analogue that extends the duration of GH-releasing hormone pulses. Ipamorelin is a selective ghrelin receptor agonist that stimulates GH release with minimal effect on cortisol or prolactin. Together, they amplify natural GH pulsatility in research models.

Key references: Ionescu & Frohman, 2006 (PMID 16352683) · Raun et al., 1998 (PMID 9849822)